Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

Manufacturing Management Team

Mike Annice
Managing Director

Kirsty Ireland
Finance Director

Andrew Parkinson
Quality Director

Gareth Davies
Sales and Marketing Director

What we do

We manufacture the vast majority of our own branded, licensed pharmaceutical products which are marketed through DVP; we also derive revenue from third party toll manufacturing for human pharmaceutical and other veterinary companies. This is Dechra's only significant source of revenue not derived directly from the veterinary market.

Operational Structure

The business has an operating board of four senior managers. The majority of manufacturing is located at Dales in Skipton, England and employs 209 people and at Eurovet in Bladel, the Netherlands which employs 106 people. There is also a small manufacturing facility in Uldum, Denmark which employs 26 people.

Our Market

The primary customer for our manufacturers is DVP EU. Our toll manufacturing customers are, in the majority, small or mid-sized UK based pharmaceutical companies. However, we also supply a number of other animal health businesses.

Key Strengths

Our ability to be flexible on batch size is a major advantage, especially when introducing new pharmaceuticals. Another key strength is our ability to produce several dosage formats such as sterile injectables, tablets, capsules, liquids, creams, gels, powders and pre-medicated feeds. We have the capacity to package these products in numerous formats. We are also able to provide a full service for third party customers including product formulation, trial batch manufacturing, validation, production and packaging.


The biggest single achievement at Dales in the year was the FDA approval in November 2011 to manufacture 120mg Vetoryl for sale in the USA market. This approval, once extended into other dosage strengths of Vetoryl, will allow us to improve the margin on our leading product. Work has also commenced to extend FDA approval into other products and dosage forms so we can manufacture other novel products in our pipeline for the USA. A Medicines and Healthcare Regulatory Agency ("MHRA") audit was conducted over the period which achieved the highest audit standard in our history. Over £1 million of new contract business has been gained at Dales in the year which resulted in a 6.1% increase compared to the corresponding period last year. Service levels have improved within the organisation, achieving 95% of lines fulfilled on time. Furthermore, there has been continued product mix rationalisation, whereby lower value and inefficiently manufactured products have been deleted. This has resulted in an increase in unit added value of 9%. Significant investment has been made at the Dales site with an upgrade in the injections facility, including a new replacement autoclave and laboratory expansion in both the quality control laboratory and the product development formulation laboratory. The key focus of the manufacturing management team in the forthcoming year will be the integration of the Eurovet site at Bladel into the Group.


We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.